Comparative effectiveness of antifungal agents in patients with hematopoietic stem cell transplantation: a systematic review and network meta-analysis

References

• Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47(8):1041–1050. doi:10.1086/5918781877
   PubMed Web of Science ®Google Scholar
• Mikulska M, Raiola AM, Bruno B, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant. 2009;44(6):361–370. doi:10.1038/bmt.2009.3919308042
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–1100. doi:10.1086/65126320218877
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow transplant. 2009;15(10):1143–1238. doi:10.1016/j.bbmt.2009.06.01919747629
   PubMed Web of Science ®Google Scholar
• Bow EJ, Vanness DJ, Slavin M, et al. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infect Dis. 2015;15:128. doi:10.1186/s12879-015-0855-625887385
   PubMed Web of Science ®Google Scholar
• Chen Q, Lin MH, Chen ML, Liu ZY, Chai D, Wang R. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials. Chin Med J. 2012;125(2):345–351.22340571
   PubMed Web of Science ®Google Scholar
• Ping B, Zhu Y, Gao Y, Yue C, Wu B. Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis. Ann Hematol. 2013;92(6):831–839. doi:10.1007/s00277-013-1693-523455400
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol. 2005;131(1):22–28. doi:10.1111/j.1365-2141.2005.05727.x16173959
   PubMed Web of Science ®Google Scholar
• Wang JF, Xue Y, Zhu XB, Fan H. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs. Eur J Clin Microbiol Infect Dis. 2015;34(4):651–659. doi:10.1007/s10096-014-2287-425502737
   PubMed Web of Science ®Google Scholar
• Xu SX, Shen JL, Tang XF, Feng B. Newer antifungal agents for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis. Transplant Proc. 2013;45(1):407–414. doi:10.1016/j.transproceed.2012.07.14923375330
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Kourbeti IS, Mylonakis E. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Clin Ther. 2014;36(2):292–306.e291.24439393
   PubMed Web of Science ®Google Scholar
• Lee CH, Lin C, Ho CL, Lin JC. Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials. Antimicrob Agents Chemother. 2018;62(8). doi:10.1128/AAC.00355-18
   Web of Science ®Google Scholar
• Leonart LP, Tonin FS, Ferreira VL, et al. A network meta-analysis of primary prophylaxis for invasive fungal infection in haematological patients. J Clin Pharm Ther. 2017;42(5):530–538. doi:10.1111/jcpt.1257928620958
   PubMed Web of Science ®Google Scholar
• Zhao YJ, Khoo AL, Tan G, et al. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis. Antimicrob Agents Chemother. 2016;60(1):376–386. doi:10.1128/AAC.01985-1526525782
   PubMed Web of Science ®Google Scholar
• Mills EJ, Ioannidis JP, Thorlund K, Schunemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. Jama. 2012;308(12):1246–1253. doi:10.1001/2012.jama.1122823011714
   PubMed Web of Science ®Google Scholar
• Green S, Higgins JP. Cochrane handbook for systematic reviews of interventions version 5.1. 0., on The Cochrane Collaboration. Available from: http://handbook.cochrane.org/. Accessed Spetember 2018.
   Google Scholar
• Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7–14. doi:10.1086/32333511731939
   PubMed Web of Science ®Google Scholar
• Mbuagbaw L, Rochwerg B, Jaeschke R, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017;6(1):79. doi:10.1186/s13643-017-0473-z28403893
   PubMed Web of Science ®Google Scholar
• Park S, Kim K, Jang JH, et al. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. J Infect. 2016;73:496–505. doi:10.1016/j.jinf.2016.06.01127394404
   PubMed Web of Science ®Google Scholar
• Huang X, Chen H, Han M, et al. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2012;18(10):1509–1516. doi:10.1016/j.bbmt.2012.02.00222469884
   PubMed Web of Science ®Google Scholar
• Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155(3):318–327. doi:10.1111/j.1365-2141.2010.08188.x21880032
   PubMed Web of Science ®Google Scholar
• Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–5118. doi:10.1182/blood-2010-02-26815120826719
   PubMed Web of Science ®Google Scholar
• Hiramatsu Y, Maeda Y, Fujii N, et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol. 2008;88(5):588–595. doi:10.1007/s12185-008-0196-y19039629
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–347. doi:10.1056/NEJMc06319017251530
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–1416. doi:10.1086/42231215546073
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138(9):705–713. doi:10.7326/0003-4819-138-9-200305060-0000612729424
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527–1533. doi:10.1182/blood-2003-08-264414525770
   PubMed Web of Science ®Google Scholar
• Annaloro C, Oriana A, Tagliaferri E, et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica. 1995;80(6):512–517.8647515
   PubMed Web of Science ®Google Scholar
• Chaftari AM, Hachem RY, Ramos E, et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. Transplantation. 2012;94(3):302–308. doi:10.1097/TP.0b013e318254dae122814329
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845–851. doi:10.1056/NEJM1992032632613011542320
   PubMed Web of Science ®Google Scholar
• Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol. 2002;71(4):260–267. doi:10.1002/(ISSN)1096-865212447954
   PubMed Web of Science ®Google Scholar
• Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med. 1994;97(6):509–514. doi:10.1016/0002-9343(94)90345-X7985709
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation–a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–1552.7769290
   PubMed Web of Science ®Google Scholar
• Wolff SN, Fay J, Stevens D, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant. 2000;25(8):853–859. doi:10.1038/sj.bmt.170223310808206
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–e93. doi:10.1093/cid/cir07321258094
   PubMed Web of Science ®Google Scholar
• Ko BS, Chen WT, Kung HC, et al. 2016 guideline strategies for the use of antifungal agents in patients with hematological malignancies or hematopoietic stem cell transplantation recipients in Taiwan. J Microbiol Immunol Infect. 2018;51(3):287–301. doi:10.1016/j.jmii.2017.07.00528781151
   PubMedGoogle Scholar
• Baden LR, Swaminathan S, Angarone M, et al. Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Nat Compr Cancer Network. 2016;14(7):882–913. doi:10.6004/jnccn.2016.0093
   PubMed Web of Science ®Google Scholar
• Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018;97(2):197–207. doi:10.1007/s00277-017-3196-229218389
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant. 2011;46(5):709–718. doi:10.1038/bmt.2010.17520661235
   PubMed Web of Science ®Google Scholar
• Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Cytotherapy. 2001;3(1):41–54.12028843
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003;21(24):4615–4626. doi:10.1200/JCO.2003.04.05214673051
   PubMed Web of Science ®Google Scholar
• Hamza NS, Ghannoum MA, Lazarus HM. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2004;34(5):377–389. doi:10.1038/sj.bmt.170460315247928
   PubMed Web of Science ®Google Scholar